Erste Group Bank Estimates Gilead Sciences FY2027 Earnings

Key Points

• Erste Group Bank raised its FY2027 EPS estimate for Gilead Sciences to $9.88 from $9.86. Analyst sentiment remains positive overall, with MarketBeat reporting a “Moderate Buy” consensus rating and an average price target of $158.78.
• Gilead’s latest quarterly results beat expectations, with adjusted EPS of $(6.75) versus $(7.25) expected and revenue of $7.80 billion, up 10.6% year over year.
• The company declared a quarterly dividend of $0.82 per share, equal to an annualized $3.28 payout and a 2.2% yield. Shares opened at $150.11, near their 52-week high of $157.29.

Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Investment analysts at Erste Group Bank upped their FY2027 earnings per share estimates for Gilead Sciences in a note issued to investors on Friday, September 18th. Erste Group Bank analyst H. Engel now anticipates that the biopharmaceutical company will post earnings per share of $9.88 for the year, up from their prior forecast of $9.86. The consensus estimate for Gilead Sciences' current full-year earnings is ($0.48) per share.

Several other equities research analysts also recently issued reports on GILD. Barclays lowered their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 29th. Truist Financial reduced their target price on shares of Gilead Sciences from $157.00 to $156.00 and set a "buy" rating for the company in a research note on Tuesday, July 7th. Royal Bank Of Canada increased their target price on Gilead Sciences from $120.00 to $123.00 and gave the stock a "sector perform" rating in a report on Wednesday, August 5th. Wall Street Zen raised Gilead Sciences from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Weiss Ratings upgraded Gilead Sciences from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, September 14th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $158.78.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $150.11 on Monday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The company has a market capitalization of $186.13 billion, a P/E ratio of -56.22 and a beta of 0.33. The company's 50 day moving average price is $139.98 and its two-hundred day moving average price is $136.22. Gilead Sciences has a 52 week low of $108.46 and a 52 week high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business had revenue of $7.80 billion for the quarter, compared to analysts' expectations of $7.40 billion. During the same quarter in the previous year, the business posted $2.01 EPS. Gilead Sciences's revenue for the quarter was up 10.6% on a year-over-year basis.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. Gilead Sciences's dividend payout ratio is currently -122.85%.

Insider Buying and Selling

In related news, Director Jeffrey Bluestone sold 5,000 shares of the firm's stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the transaction, the director directly owned 10,066 shares of the company's stock, valued at approximately $1,459,771.32. This trade represents a 33.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of the business's stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $145.29, for a total transaction of $435,870.00. Following the transaction, the chief financial officer owned 164,096 shares in the company, valued at approximately $23,841,507.84. The trade was a 1.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 105,000 shares of company stock worth $14,616,390 in the last quarter. 0.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new stake in Gilead Sciences in the second quarter valued at approximately $15,393,785,000. State Street Corp increased its holdings in shares of Gilead Sciences by 1.9% in the fourth quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company's stock valued at $7,393,921,000 after purchasing an additional 1,151,213 shares during the last quarter. Norges Bank bought a new stake in shares of Gilead Sciences during the 4th quarter worth about $2,617,152,000. Invesco Ltd. grew its stake in Gilead Sciences by 2.9% in the 4th quarter. Invesco Ltd. now owns 15,584,341 shares of the biopharmaceutical company's stock valued at $1,912,822,000 after buying an additional 444,660 shares during the last quarter. Finally, Amundi grew its stake in Gilead Sciences by 10.7% in the 1st quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company's stock valued at $1,468,836,000 after buying an additional 1,018,976 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company's research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.

Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.